ODs: Here's what your patients tweeted about you in August, 2020

Article

Find out what your patients are tweeting about you.

ODs know now to add 3 extra hours, for good measure.

😂

True.

It's not to late to schedule your next appointment in time for Halloween!

🤘

🤠

We love to see it!

oh snap!

What do you think ODs? rude? fun?

When it's true, it's true.

Related: ODs: Here's what your patients tweeted about you in July, 2020

Recent Videos
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Alysse Henkel, vice president of Research and inSights at The Vision Council, advised that expanding budget and mid-market frame options may help improve frames sales.
Steven T. Reed, OD, American Optometric Association's president, overviews the 2024 highlights and how the organization plans to extend success into 2025.
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2025 MJH Life Sciences

All rights reserved.